login
Become a member
Quick Registration
Full Registration Benefits -
Free Homepages for Doctors
Free Homepages for Hospitals
Free Homepages for Medical Conference
Free Homepages for NGO's
Personal Health Record Creation
Access to all Medical Slides
Access to all Jobs & Products Sale
Medindia »
Consumer Health »
Health Information »
Latest Publication and Research on Acute Myeloid Leukemia
| Disease Info Index | ||||||||||||||||||||||||||
|
|
Acute Myeloid Leukemia
Page Options
Drugs For Acute Myeloid Leukemia
busulphan
chlorambucil
cyclophosphamide
cytarabine
daunorubicin
doxorubicin
hydroxyurea
idarubicin
leucovorin
methotrexate
mitoxantrone
prednisone
sargramostim
tretinoin
vincristine
Acute Myeloid Leukemia
Latest Publication and Research on Acute Myeloid Leukemia
|
|
|
Text 
|
2011 Dec 5 Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation. Yoshioka Y, Ono M, Osaki M, Konishi I, Sakaguchi S Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan. The abbreviations used are: DM, dorsomorphin; BMP, bone morphogenic protein; BMPR, BMP receptor; rBMP2, recombinant BMP2; rNoggin, recombinant Noggin;... Read More Source: PubMed 2011 Dec 6 The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J 1] Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France [2] Inserm, U1016, Paris, France [3] Service de Médecine Interne-UF d'Hématologie, Hôpital Cochin, AP-HP, Paris, France. The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in prim... Read More Source: PubMed Comparable Analysis of Outcomes for Allogeneic Peripheral Blood Stem Cell Transplantation from Matched Related and Matched Unrelated Donors in Acute Myeloid Leukemia. Lee SJ, Kang BW, Moon JH, Chae YS, Kim JG, Jung JS, Cho GJ, Jo DY, Kim YK, Kim HJ, Ryoo HM, Eom HS, Le SM, Joo YD, Won JH, Park MR, Kim MK, Hyun MS, Sohn SK Departments of Hematology and Oncology, Kyungpook National University Hospital, Daegu, South Korea. This study compared the results of allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated and related donors in 142 consecutive ... Read More Source: PubMed 2011 Dec 5 Design of Novel FLT-3 Inhibitors Based on Dual-layer 3D-QSAR Model and Fragment-Based Compounds in Silico Shih KC, Lin CY, Zhou J, Chi HC, Hwang CS, Chen TS, Tang CY, Hsiao NW In this study, FMS-like tyrosine kinase 3 (FLT-3) was chosen as a target owing to its strong correlation with acute myeloid leukemia (AML), and there ... Read More Source: PubMed 2011 Dec 2 Myelodysplastic syndrome in a child with 15q24 deletion syndrome. Narumi Y, Shiohara M, Wakui K, Hama A, Kojima S, Yoshikawa K, Amano Y, Kosho T, Fukushima Y Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto, Japan. ynarumi@shinshu-u.ac.jp. 15q24 deletion syndrome is a recently-described chromosomal disorder, characterized by developmental delay, growth deficiency, distinct facial feature... Read More Source: PubMed 2011 Dec 2 A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. hkhoury@emory.edu. BACKGROUND: ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis... Read More Source: PubMed 2011 Dec 2 CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML). Shiba N, Hasegawa D, Park MJ, Murata C, Matsubara A, Ogawa C, Manabe A, Arakawa H, Ogawa S, Hayashi Y Department of Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Japan; Familial platelet disorder with a propensity to develop acute myeloid leukemia (FPD/AML) is a rare autosomal dominant disease characterized by thrombo... Read More Source: PubMed 2011 Nov 12 Novel chromosomal translocation (17;22)(q12;q12) in a case of myelodisplastic syndrome characterized with signs of hemolytic anemia at presentation. Antic D, Impera L, Fekete MD, Djordjevic V, Storlazzi CT, Elezovic I Clinic for hematology, Clinical Center Serbia, Koste Todorovica 2, 11 000 Belgrade, Serbia. Myelodysplastic syndromes (MDS) are clonal stem cell diseases that can result in cytopenias, dysplasia in one or more cell lineages, infective hematop... Read More Source: PubMed 2011 Dec 1 Clinical profile and outcome of patients of acute myeloid leukemia with high hyperdiploidy. Sharma SK, Sharma M, Seth T, Mishra P, Chowdhry M, Mahapatra M, Saxena R Department of Hematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. ... Read More Source: PubMed 2011 Dec 5 Differential effects of inhibition of bone morphogenic protein (BMP) signalling on T-cell activation and differentiation. Yoshioka Y, Ono M, Osaki M, Konishi I, Sakaguchi S Department of Gynecology and Obstetrics, Graduate School of Medicine, Kyoto University, Kyoto, Japan; Department of Experimental Pathology, Institute for Frontier Medical Sciences, Kyoto University, Kyoto, Japan. The abbreviations used are: DM, dorsomorphin; BMP, bone morphogenic protein; BMPR, BMP receptor; rBMP2, recombinant BMP2; rNoggin, recombinant Noggin;... Read More Source: PubMed 2011 Dec 6 The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. Willems L, Chapuis N, Puissant A, Maciel TT, Green AS, Jacque N, Vignon C, Park S, Guichard S, Herault O, Fricot A, Hermine O, Moura IC, Auberger P, Ifrah N, Dreyfus F, Bonnet D, Lacombe C, Mayeux P, Bouscary D, Tamburini J 1] Institut Cochin, Université Paris Descartes, CNRS (UMR8104), Paris, France [2] Inserm, U1016, Paris, France [3] Service de Médecine Interne-UF d'Hématologie, Hôpital Cochin, AP-HP, Paris, France. The serine/threonine kinase mammalian target of rapamycin (mTOR) is crucial for cell growth and proliferation, and is constitutively activated in prim... Read More Source: PubMed Comparable Analysis of Outcomes for Allogeneic Peripheral Blood Stem Cell Transplantation from Matched Related and Matched Unrelated Donors in Acute Myeloid Leukemia. Lee SJ, Kang BW, Moon JH, Chae YS, Kim JG, Jung JS, Cho GJ, Jo DY, Kim YK, Kim HJ, Ryoo HM, Eom HS, Le SM, Joo YD, Won JH, Park MR, Kim MK, Hyun MS, Sohn SK Departments of Hematology and Oncology, Kyungpook National University Hospital, Daegu, South Korea. This study compared the results of allogeneic peripheral blood stem cell transplantation (PBSCT) from unrelated and related donors in 142 consecutive ... Read More Source: PubMed 2011 Dec 5 Design of Novel FLT-3 Inhibitors Based on Dual-layer 3D-QSAR Model and Fragment-Based Compounds in Silico Shih KC, Lin CY, Zhou J, Chi HC, Hwang CS, Chen TS, Tang CY, Hsiao NW In this study, FMS-like tyrosine kinase 3 (FLT-3) was chosen as a target owing to its strong correlation with acute myeloid leukemia (AML), and there ... Read More Source: PubMed 2011 Dec 2 Myelodysplastic syndrome in a child with 15q24 deletion syndrome. Narumi Y, Shiohara M, Wakui K, Hama A, Kojima S, Yoshikawa K, Amano Y, Kosho T, Fukushima Y Department of Medical Genetics, Shinshu University School of Medicine, Matsumoto, Japan. ynarumi@shinshu-u.ac.jp. 15q24 deletion syndrome is a recently-described chromosomal disorder, characterized by developmental delay, growth deficiency, distinct facial feature... Read More Source: PubMed 2011 Dec 2 A phase 1 dose-escalation study of ARRY-520, a kinesin spindle protein inhibitor, in patients with advanced myeloid leukemias. Khoury HJ, Garcia-Manero G, Borthakur G, Kadia T, Foudray MC, Arellano M, Langston A, Bethelmie-Bryan B, Rush S, Litwiler K, Karan S, Simmons H, Marcus AI, Ptaszynski M, Kantarjian H Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia. hkhoury@emory.edu. BACKGROUND: ARRY-520 selectively inhibits the mitotic kinesin spindle protein (KSP), which leads to abnormal monopolar spindle formation and apoptosis... Read More Source: PubMed 2011 Dec 2 CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD/AML). Shiba N, Hasegawa D, Park MJ, Murata C, Matsubara A, Ogawa C, Manabe A, Arakawa H, Ogawa S, Hayashi Y Department of Hematology/Oncology, Gunma Children's Medical Center, Shibukawa, Japan; Familial platelet disorder with a propensity to develop acute myeloid leukemia (FPD/AML) is a rare autosomal dominant disease characterized by thrombo... Read More Source: PubMed 2011 Nov 12 Novel chromosomal translocation (17;22)(q12;q12) in a case of myelodisplastic syndrome characterized with signs of hemolytic anemia at presentation. Antic D, Impera L, Fekete MD, Djordjevic V, Storlazzi CT, Elezovic I Clinic for hematology, Clinical Center Serbia, Koste Todorovica 2, 11 000 Belgrade, Serbia. Myelodysplastic syndromes (MDS) are clonal stem cell diseases that can result in cytopenias, dysplasia in one or more cell lineages, infective hematop... Read More Source: PubMed 2011 Dec 1 Clinical profile and outcome of patients of acute myeloid leukemia with high hyperdiploidy. Sharma SK, Sharma M, Seth T, Mishra P, Chowdhry M, Mahapatra M, Saxena R Department of Hematology, All India Institute of Medical Sciences, Ansari Nagar, New Delhi, India. ... Read More Source: PubMed 2011 Dec 2 Fatigue in survivors of childhood acute lymphoblastic and myeloid leukemia in Japan. Nagai A, Ning Z, Kubota M, Kojima C, Adachi S, Usami I, Okada M, Tanizawa A, Hamahata K, Matsubara K, Higuchi M, Imaizumi M Faculty of Human Life and Environment, Nara Women's University, Nara, Japan Department of Pediatrics, Kyoto University Hospital, Kyoto, Japan Department of Pediatrics, Kobe City Medical Center General Hospital, Kobe, Japan Department of Pediatrics, Tenri Hospital, Tenri, Japan Department of Pediatrics, Fukui University Hospital, Fukui, Japan Department of Pediatrics, Wakayama Red Cross Medical Center, Wakayama, Japan Department of Pediatrics, Nishi-Kobe Medical Center, Kobe, Japan Department of Pediatrics, Nara Medical University Hospital, Nara, Japan Department of Pediatrics, Miyagi Children's Hospital, Miyagi, Japa. Background: Fatigue in cancer survivors is a serious problem in pediatric oncology. However, reports on this issue are limited, especially in Asian c... Read More Source: PubMed 2011 Dec 2 Fatigue in survivors of childhood acute lymphoblastic and myeloid leukemia in Japan. Nagai A, Ning Z, Kubota M, Kojima C, Adachi S, Usami I, Okada M, Tanizawa A, Hamahata K, Matsubara K, Higuchi M, Imaizumi M Faculty of Human Life and Environment, Nara Women's University, Nara, Japan Department of Pediatrics, Kyoto University Hospital, Kyoto, Japan Department of Pediatrics, Kobe City Medical Center General Hospital, Kobe, Japan Department of Pediatrics, Tenri Hospital, Tenri, Japan Department of Pediatrics, Fukui University Hospital, Fukui, Japan Department of Pediatrics, Wakayama Red Cross Medical Center, Wakayama, Japan Department of Pediatrics, Nishi-Kobe Medical Center, Kobe, Japan Department of Pediatrics, Nara Medical University Hospital, Nara, Japan Department of Pediatrics, Miyagi Children's Hospital, Miyagi, Japa. Background: Fatigue in cancer survivors is a serious problem in pediatric oncology. However, reports on this issue are limited, especially in Asian c... Read More Source: PubMed |
| Share it! |  |
 |
 |
 |
 |
 |
 |
|
|
Comment & Contribute
|
Posted by:
Ravikohli
Posted on: 02/28/2012 I have Acute Leukemia[AML] cancer to my sister. Her age is 25 years. In recent test reports Blast are about 80%.
Can you please tell me how i can proceed to cure my sister.
Reply |
Forward
Posted by:
Nimat(Guest)
Posted on: 02/02/2011 Hello.i just read about AML and i am satisfied with the information providede. Though i have one small enquiry; Anthracycline has been listed as one of the drugs given during Chemotherapy that may cause AML in the future and yet it has been listed as a drug for treating AML. Doess it mean that you are at risk of contracting AML again? I will apprecite your assistance on this qustion..
Posted by:
simipaknikar(Guest)
Posted on: 02/06/2011 Anthracyclines have been found to produce AML in patients who underwent treatment for breast cancer and Hodgkin's lymphoma, especially when used with other anticancer drugs and in high doses. Currently anthracyclines are very effective in AML, and the risk of them causing AML are small, hence they are used in AML. |
|
Posted by:
BALAKRISHNAN
Posted on: 07/06/2010 There is a research case report on certain ayrvedic drugs on Cancer (Myelofibrosis) in the google search. I think there is medicine for this disease in Ayurveda. And one of my relatives is undergoing ayrvedic treatment for myelofibrosis after it was detected from Manipal Medical College and advised there is no treatment for this in allopathy.
Posted by:
Johanna(Guest)
Posted on: 12/14/2009 hi, my father has Acute Myeloid Leukemia and an under lying condition of myloid fibrosis. He has no other side effects and often only feels tired with leg pains. It appears the cancer has come back. Has anyone tried any alternate therapies? He is on a clinical trial and seems to be baffling his doctors. Any advice?
Posted by:
abelzkie
Posted on: 11/04/2009 my sister was diagnosed with AML and she is in her second year now since she was diagnosed last year. She is ok as of now after her low dose of chemotherapy. I know that prognosis of this disease is poor. Is there patients having this kind of leukemia survived? Is there a possibility that she might respond to bone marrow transplant? Please help me to find support group that offers financial supports. Pls. let me know. Thanks. |
| View all Comments (13) | ||
| Related Links | ||||||||||||||
|
Medwonders Health Network
| Citing this Health Article | ||||||
|
||||||
| News on Acute Myeloid Leukemia |
Are you a member of Facebook? Become a fan of Medindia and get breaking news delivered to your Facebook page.
